Arecor at World Congress’ Biologics Formulation and Drug Delivery Technologies Summit


Arecor Limited, the UK-based leading formulation technology company, focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides enabling the improved treatment of diabetes and other conditions, is pleased to announce its participation at The World Congress’ Biologics Formulation and Drug Delivery Technologies Summit, on 21st and 22nd May 2018, at the Hilton Hotel, Boston, Massachusetts, USA.

Arecor’s Chief Scientific Officer, Dr Jan Jezek, and the Company’s Technical Lead, Dr Nick Darton, will both be presenting at this leading international forum for the discussion of formulation strategies for developing stable and highly concentrated biologics and a forum for the exploration of next generation drug delivery technologies that will cover novel drug delivery approaches and the role of technologies in improving the efficacy and safety of delivering biologics.

Dr Jezek will present a talk on ‘Development of successful injectable products via innovative formulation and state-of-the-art delivery devices’, held at 14:30 on Monday, 21st May 2018.

Dr Jezek will also take part in a discussion panel ‘Partnerships & collaborations: establish partnerships to create novel biologics drug delivery systems & improve business development goals’, held at 16:15 on Monday, 21st May 2018.

Dr Darton will present a talk on ‘Parenteral drug delivery: discover parenteral formulation strategies for peptide and protein biologics’, held at 12:15 on Tuesday, 22nd May 2018.

Attendees will benefit from 30+ presentations focused on biologic formulation strategies, novel biologics delivery approaches, technologies and partnerships to develop innovative formulation and delivery strategies of biologics.  The Speaking faculty are drawn from leading figures in industry and academia and presentations will explore how to:

  • Develop novel formulation strategies to enhance the design and delivery of high dose biologic formulations; 
  • Establish drug delivery partnerships to improve life cycle management and establish strategies for biologic drug development; 
  • Understand how to maintain molecular stability and predict protein stability; 
  • Ensure patient centricity in drug formulation to achieve a competitive advantage through ensuring quality and enhancing the patient experience.

About ArestatTM

Arecor has significant experience and a proven track record in applying the ArestatTM formulation technology platform to deliver superior biopharmaceutical product profiles across a broad range of proteins, peptides and vaccines.

About Arecor Limited (

Arecor Ltd is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.

In addition to its internal product portfolio, Arecor is currently leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides.  Arecor's product portfolio also includes:

  • Ultra-concentrated insulin to enable the miniaturisation of devices
  • Novel insulin formulations to deliver ultra-rapid acting insulin analogs
  • Stable aqueous glucagon for emergency and artificial pancreas use

Arecor’s product pipeline and progress towards not only enabling the miniaturization of next-generation insulin delivery technologies, but also offering superior treatment and quality of life for people requiring large doses of insulin to manage their condition, is hugely exciting.  Indeed, the Company has announced the successful pre-clinical development of its ultra-concentrated rapid acting insulin product and it looks forward to Arecor’s propriety product’s advance this year into a first-in-human clinical study in patients with Type 1 diabetes.

For more information, please contact:    

Dr Laura AS Ciccolini, Director of Business Development, Licensing & PR/Marketing               


To read more information, click here.

Advancing today's therapies to enable healthier lives.

Arecor Therapeutics Plc